302 related articles for article (PubMed ID: 15297420)
21. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization.
Günther K; Merkelbach-Bruse S; Amo-Takyi BK; Handt S; Schröder W; Tietze L
J Pathol; 2001 Jan; 193(1):40-7. PubMed ID: 11169514
[TBL] [Abstract][Full Text] [Related]
22. Her-2/neu gene amplification in ductal carcinoma in situ of the breast.
Hoque A; Sneige N; Sahin AA; Menter DG; Bacus JW; Hortobagyi GN; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101
[TBL] [Abstract][Full Text] [Related]
23. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
24. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast.
Chuaqui RF; Zhuang Z; Emmert-Buck MR; Liotta LA; Merino MJ
Am J Pathol; 1997 Jan; 150(1):297-303. PubMed ID: 9006344
[TBL] [Abstract][Full Text] [Related]
25. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
26. Timing of critical genetic changes in human breast disease.
Ellsworth RE; Ellsworth DL; Deyarmin B; Hoffman LR; Love B; Hooke JA; Shriver CD
Ann Surg Oncol; 2005 Dec; 12(12):1054-60. PubMed ID: 16228814
[TBL] [Abstract][Full Text] [Related]
27. Chromosomal alterations in pure nonneoplastic breast lesions: implications for breast cancer progression.
Ellsworth RE; Ellsworth DL; Weyandt JD; Fantacone-Campbell JL; Deyarmin B; Hooke JA; Shriver CD
Ann Surg Oncol; 2010 Jun; 17(6):1688-94. PubMed ID: 20107913
[TBL] [Abstract][Full Text] [Related]
28. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type.
Vos CB; ter Haar NT; Rosenberg C; Peterse JL; Cleton-Jansen AM; Cornelisse CJ; van de Vijver MJ
Br J Cancer; 1999 Dec; 81(8):1410-8. PubMed ID: 10604741
[TBL] [Abstract][Full Text] [Related]
29. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
30. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
[TBL] [Abstract][Full Text] [Related]
32. Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization.
Mendelin J; Grayson M; Wallis T; Visscher DW
Lab Invest; 1999 Apr; 79(4):387-93. PubMed ID: 10211991
[TBL] [Abstract][Full Text] [Related]
33. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
[TBL] [Abstract][Full Text] [Related]
34. Genetic pathways in the evolution of breast ductal carcinoma in situ.
Farabegoli F; Champeme MH; Bieche I; Santini D; Ceccarelli C; Derenzini M; Lidereau R
J Pathol; 2002 Mar; 196(3):280-6. PubMed ID: 11857490
[TBL] [Abstract][Full Text] [Related]
35. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
36. Genetic divergence in the clonal evolution of breast cancer.
Fujii H; Marsh C; Cairns P; Sidransky D; Gabrielson E
Cancer Res; 1996 Apr; 56(7):1493-7. PubMed ID: 8603391
[TBL] [Abstract][Full Text] [Related]
37. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
38. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization.
Rennstam K; Ahlstedt-Soini M; Baldetorp B; Bendahl PO; Borg A; Karhu R; Tanner M; Tirkkonen M; Isola J
Cancer Res; 2003 Dec; 63(24):8861-8. PubMed ID: 14695203
[TBL] [Abstract][Full Text] [Related]
39. Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases.
Wagner PL; Kitabayashi N; Chen YT; Shin SJ
Am J Clin Pathol; 2009 Dec; 132(6):871-6. PubMed ID: 19926578
[TBL] [Abstract][Full Text] [Related]
40. Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ.
Aulmann S; Elsawaf Z; Penzel R; Schirmacher P; Sinn HP
Am J Surg Pathol; 2009 Nov; 33(11):1646-53. PubMed ID: 19675453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
